Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30192680 | 1.00 | TDP1 (0.49) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL1390651 | 1.00 | TDP1 (0.49) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL1547216 | 1.00 | TDP1 (0.49) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL30192877 | 1.00 | TDP1 (0.49) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL7747146 | 0.82 | TDP1 (0.50) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL7352195 | 0.82 | TDP1 (0.50) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL11408262 | 0.80 | TDP1 (0.53) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL963795 | 0.79 | TDP1 (0.57) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL5421950 | 0.78 | TDP1 (0.47) | TDP1LMNACASP3ALDH1A1HTT | |
| SCHEMBL6656473 | 0.76 | TDP1 (0.57) | TDP1LMNACASP3ALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285377-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. | 2023-09-14 | — | — | US | disclosed |
| EP-4125831-A2 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-11345703-B2 | Substituted pyrazolo[1,5-a]pyrimidine macrocyclic compound | SHENZHEN TARGETRX, INC. (CN) | 2022-05-31 | — | — | US | disclosed |
| WO-2021195066-A2 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| US-20210047330-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND | SHENZHEN TARGETRX, INC. (CN) | 2021-02-18 | — | — | US | disclosed |
| CN-111592541-A | Macrocyclic kinase inhibitors and uses thereof | 山东轩竹医药科技有限公司 | 2020-08-28 | — | — | CN | disclosed |
| WO-2019144885-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND | 深圳市塔吉瑞生物医药有限公司 | 2019-08-01 | — | — | WO | disclosed |
| US-8748627-B2 | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome | ABBVIE INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20070225332-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ABBVIE INC. | 2007-09-27 | — | — | US | disclosed |
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | ERBB2, ERBB4, ERBB3 | TDP1 675/4885LMNA 4738/4885CASP3 4801/4885 |
| US-11345703-B2 | Substituted pyrazolo[1,5-a]pyrimidine macrocyclic compound | DMPK, MAPKAPK5, VRK2 | TDP1 988/4885LMNA 4236/4885CASP3 878/4885 |
| US-20230285377-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | TDP1 1280/4885LMNA 1423/4885CASP3 4106/4885 |
| US-20210047330-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE MACROCYCLIC COMPOUND | DMPK, MAPKAPK5, VRK2 | TDP1 988/4885LMNA 4236/4885CASP3 878/4885 |
| US-20070225332-A1 | NOVEL ACETYL-COA CARBOXYLASE (ACC) INHIBITORS AND THEIR USE IN DIABETES, OBESITY AND METABOLIC SYNDROME | ACACA, ACACB, ACAT1 | TDP1 4732/4885LMNA 3484/4885CASP3 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.